Description

Chronic liver disease (CLD) is a pandemic healthcare problem affecting about 1.5 billion people worldwide. Diagnosis of liver fibrosis plays a key role in the clinical management of patients with CLD. The current gold standard for diagnosis of liver fibrosis is liver biopsy, which is invasive, costly, and unsuitable for screening and treatment monitoring. The existing non-invasive methods still have significant limitations to diagnose liver fibrosis.

Based on our research outcome at CUHK, our company aims to commercialize a non-invasive diagnostic technology to detect biochemical symptoms of diseases before any anatomical symptoms manifest. The technology has potential to be used for early diagnosis and treatment monitoring of diseases. A main goal of our company is to apply this technology for diagnosis of liver fibrosis and a comprehensive assessment of CLD.